<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03723135</url>
  </required_header>
  <id_info>
    <org_study_id>CC-486</org_study_id>
    <nct_id>NCT03723135</nct_id>
  </id_info>
  <brief_title>Expanded Access for CC-486</brief_title>
  <official_title>Expanded Access for CC-486</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <brief_summary>
    <textblock>
      This is an expanded access program (EAP) for eligible participants designed to provide access
      to CC-486.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Acute Myelogenous Leukemia (AML)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-486</intervention_name>
    <description>Oral azacitidine administered as directed by treating physician.</description>
    <other_name>Oral Azacitidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Adult patients with documented acute myelogenous leukemia (AML) in their first complete
        remission (CR) or complete remission with incomplete blood count recovery (CRi) following
        induction therapy with or without consolidation treatment, who seek treatment with CC-486
        as monotherapy to maintain their CR or CRi.

        Exclusion Criteria:

          -  Patients with AML in CR/CRi who plan to proceed to or are waiting for a bone marrow
             transplant

          -  Patients who have received a bone marrow transplant for the treatment of AML

          -  Treatment of AML patients with relapse or refractory disease

          -  Pregnant or breast-feeding females

          -  Patient meets enrollment criteria and can participate in a disease-specific clinical
             trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Celgene Medical Information</last_name>
    <phone>1-888-771-0141</phone>
    <email>PAA.CC486.SPR@bms.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Celgene</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2018</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Expanded Access</keyword>
  <keyword>Compassionate Use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

